预约演示

J&J shines light on key role in multiple myeloma care team, vowing to raise awareness and offer support

2023-09-26

免疫疗法

Johnson & Johnson wants to provide resources to advanced practice providers working in multiple myeloma.

Johnson & Johnson’s multiple myeloma team wants to “Make It HAPPen.” Working with a promultiple myelomay, the drugmaker is stepping up its support for advanced practice providers (APPs) in light of survey data showing the key role they play in the multiple myeloma care pathway.

Johnson & Johnsonbodmultiple myelomatitioners Society for Hematology and Oncology (APSHO), represents APPs such as nurse practitioners and physician assistants who do some of the same tasks as physicians. J&J, which sells multiple myeloma drugs sucmultiple myelomad Carvykti, partnered with APSHO because it sees APPs as a key part of the multiple myeloma care team that would benefit from additional support.

“APPs are what I call the backbone to the entire care team. They really see and shepherd these patients along their entire patient journey,” June Lanoue, vice president of hematology marketing and sales atJ&JJ, said.myeloma Darzalex Carvykti multiple myeloma

J&J worked with APSHO to better understand the needs of APPs, surveying 200 APPs who see multiple myeloma patients and 100 multiple myeloma patients. The poll revealed the importance of APPs. Most, 93%, of J&Jients said APPs are essential to their care, and 61% of patients said they feel they could ask an APP questions they couldn’t put to their doctor.

J&J willingness to ask APPs questions reflects the fact that the healthcare professionalsmultiple myeloma time with patientmultiple myelomae emotional support,” Lanoue said. Yet, while the survey showed the key role APPs play, it also revealed a need for additional support. Most, 94%, of APPs want more educational resources specific to multiple myeloma.

“It's not that they're not knowledgeable. It's just, they're limited in time. They are so busy,” Lanoue said. “They want to be more involved. I thought they were very close to the patient, but they want to be more involved with patient care.” APPs want to be more involved at the start of the patient journey.multiple myeloma

The survey results are informing a multiyear push. J&J wants to provide resources to APPs working in multiple myeloma, raise awareness of their role and, in doing so, support patients and physicians. Specific activities include building a central website for APPs and providing educational resources, potentially via scientific forums and webinars.

J&J is providing the support to healthcare professiJ&Jls who work in a key therapeutic area for the fmultiple myeloma38 antibody Darzalex is a cornerstone of J&J’s business, generating $2.4 billion in the second quarter, and the BCMA CAR-T cell therapy Carvykti is an important emerging opportunity.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构